An ionizable cationic lipid
Technical Support & Resources

Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

ALC-0315

Item No. 34337

Product Insert (PDF)Safety Data Sheet (SDS) (PDF)
Technical Information
Formal Name
2-hexyl-decanoic acid, 1,1'-[[(4-hydroxybutyl)imino]di-6,1-hexanediyl] ester
CAS Number
2036272-55-4
Molecular Formula
C48H95NO5
Formula Weight
766.3
Purity
≥98%
Formulation (Request formulation change)
A 250 mg/ml solution in ethanol
Solubility(Learn about Variance in Solubility)
Chloroform: 50 mg/mlEthanol: 50 mg/ml
SMILES
OCCCCN(CCCCCCOC(C(CCCCCC)CCCCCCCC)=O)CCCCCCOC(C(CCCCCC)CCCCCCCC)=O
InChi Code
InChI=1S/C48H95NO5/c1-5-9-13-17-19-27-37-45(35-25-15-11-7-3)47(51)53-43-33-23-21-29-39-49(41-31-32-42-50)40-30-22-24-34-44-54-48(52)46(36-26-16-12-8-4)38-28-20-18-14-10-6-2/h45-46,50H,5-44H2,1-4H3
InChi Key
QGWBEETXHOVFQS-UHFFFAOYSA-N
Shipping & Storage Information
Storage
-20°C
Shipping
Wet ice in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Download most recent Certificate of Analysis for this product

    25 mg

    $190

    Add

    50 mg

    $342

    Add

    100 mg

    $570

    Add

    250 mg

    $950

    Add

    1 g

    $1,600

    Add
    Cayman Chemical
    Ionizable Lipids – Your Path from R&D to GMP

    Seamlessly bridge your LNP discovery journey from RUO to bulk GLP-tox and GMP excipient-grade material.

    Explore CGMP Lipid Services
    Product Description

    ALC-0315 is an ionizable cationic lipid (pKa 6.09) that has been used in the generation of lipid nanoparticles (LNPs) for the delivery of mRNA, siRNA, and plasmid DNA in vitro and in vivo.1,2,3,4 LNPs containing ALC-0315 and encapsulating siRNA targeting Factor VII mRNA decrease Factor VII mRNA levels in hepatocytes in mice.3 Administration of severe acute respiratory coronavirus 2 (SARS-CoV-2) mRNA in ALC-0315-containing LNPs induces the production of IgG that binds to the SARS-CoV-2 receptor-binding domain (RBD) in rhesus macaques, with a boost in antigen-specific IgG geometric mean titers (GMT) seven and 14 days after a second dose. LNPs containing ALC-0315 and encapsulating ovalbumin mRNA reduce tumor volume in an ovalbumin-expressing B16/F10 murine melanoma model.5 Formulations containing ALC-0315 have been used in the development of LNPs for the delivery of mRNA-based vaccines.

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Ansell, S.M., and Du, X. Lipids and lipid nanoparticle formulations for delivery of nucleic acids. US 10,166,298 B2, (2019).

    2. Vogel, A.B., Kanevsky, I., Che, Y., et al. BNT162b vaccines protect rhesus macaques from SARS-CoV-2. Nature 592(7853), 283-289 (2021).

    3. Ferraresso, F., Strilchuk, A.W., Juang, L.J., et al. Comparison of DLin-MC3-DMA and ALC-0315 for siRNA delivery to hepatocytes and hepatic stellate cells. Mol. Pharm. 19(7), 2175-2182 (2022).

    4. Zhang, W., Pfeifle, A., Lansdell, C., et al. The expression kinetics and immunogenicity of lipid nanoparticles delivering plasmid DNA and mRNA in mice. Vaccines (Basel) 11(10), 1580 (2023).

    5. Chen, J., Ye, Z., Huang, C., et al. Lipid nanoparticle-mediated lymph node-targeting delivery of mRNA cancer vaccine elicits robust CD8+ T cell response. Proc. Natl. Acad. Sci. USA 119(34), e2207841119 (2022).

    Product Citations

    Han, E.L., Kim, D., Murray, A.M., et al. High-throughput in vivo screening identifies structural factors driving mRNA lipid nanoparticle delivery to the brain. ACS Nano 20(4), 3807-3820 (2026).

    Wojcechowskyj, J.A., Jong, R.M., Mäger, I., et al. Controlling reactogenicity while preserving immunogenicity from a self-amplifying RNA vaccine by modulating nucleocytoplasmic transport. NPJ Vaccines 10(1), 85 (2025).

    Streeter, D.J., Witkowski, J.T., Khare, G.P., et al. Mechanism of action of 1-β-D-ribofuranosyl-1,2,4-triazole-3-carboxamide (virazole), a new broad-spectrum antiviral agent. Proc. Natl. Acad. Sci. USA 70(4), 1174-1178 (1973).

    Yeo, S., Lee, H., Lee, J., et al. Optimization of polyethylene glycol shielding and mannose density on the lipid nanoparticles for efficient delivery to macrophages and spleens. Int. J. Pharm. 662, 124540 (2024).